CD4 T cell survival after intermittent interleukin-2 therapy is predictive of an increase in the CD4 T cell count of HIV-infected patients.
about
Interleukin-2 therapy in patients with HIV infection.Long-term effects of intermittent IL-2 in HIV infection: extended follow-up of the INSIGHT STALWART Study.Inferiority of IL-2 alone versus IL-2 with HAART in maintaining CD4 T cell counts during HAART interruption: a randomized controlled trial.Soluble mediators of inflammation in HIV and their implications for therapeutics and vaccine developmentImmunotherapeutic restoration in HIV-infected individuals.
P2860
CD4 T cell survival after intermittent interleukin-2 therapy is predictive of an increase in the CD4 T cell count of HIV-infected patients.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on September 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
CD4 T cell survival after inte ...... ount of HIV-infected patients.
@en
CD4 T cell survival after inte ...... ount of HIV-infected patients.
@nl
type
label
CD4 T cell survival after inte ...... ount of HIV-infected patients.
@en
CD4 T cell survival after inte ...... ount of HIV-infected patients.
@nl
prefLabel
CD4 T cell survival after inte ...... ount of HIV-infected patients.
@en
CD4 T cell survival after inte ...... ount of HIV-infected patients.
@nl
P2093
P2860
P356
P1476
CD4 T cell survival after inte ...... ount of HIV-infected patients.
@en
P2093
Chiung-Yu Huang
H Clifford Lane
Haleem J Issaq
Jorge A Tavel
Joseph A Kovacs
Joseph W Adelsberger
Marjorie Bosche
Michele Di Mascio
Richard T Davey
Rosanne Burke
P2860
P304
P356
10.1086/591250
P407
P577
2008-09-01T00:00:00Z